The Long Island Tick Thesis

SOD Sciences Inc. Science Brief. Why every failed treatment attacked the wrong target, and how the ReBaLU protocol unlocks a host-directed answer to Lyme, babesiosis, anaplasmosis, Powassan, Borrelia miyamotoi, and alpha-gal syndrome.

The Situation on Long Island

Suffolk County is now the tick-borne disease capital of the United States. Suspected Lyme cases inside the county rose from 654 in 2014 to 3,152 in 2024, and preliminary data show roughly 3,200 in 2025, a nearly fivefold explosion in a single decade according to reporting on New York State records. Alpha-gal syndrome, the tick-triggered mammalian meat allergy that can drive anaphylaxis, has been documented in 3,746 suspected Suffolk County cases between 2017 and 2022 per CDC surveillance, the highest county total in the nation and roughly four percent of all suspected United States cases in a county with less than half a percent of the population.

The blacklegged tick, Ixodes scapularis, does not carry one pathogen. On any given feeding, it can deliver Borrelia burgdorferi (Lyme), Anaplasma phagocytophilum (anaplasmosis), Babesia microti (babesiosis), Powassan virus, and Borrelia miyamotoi (relapsing fever). Powassan is the one to watch. The CDC reported 60 cases in 2024 with a 15 percent case-fatality rate, all neuroinvasive, an all-time record, and New York State has logged 59 of the 397 historical United States cases according to CDC historic data 2004 to 2024, placing it among the highest-burden states in the country. Powassan transmits in as little as fifteen minutes of tick attachment, well before a Long Island homeowner ever thinks to check.

Nationally the picture is worse. The CDC estimates approximately 476,000 Americans are affected by Lyme disease each year. Reported anaplasmosis cases in the United States climbed from 348 in 2000 to 5,655 in 2019, a sixteenfold increase in nineteen years. Every one of these numbers is heading up.

This is what Long Island has, in 2026, against a set of pathogens for which the world has essentially nothing preventive and nothing curative for the chronic phase.

Six pathogens. One shared vulnerability. One lock they all pick.

What the World Actually Has

The inventory is short. There are zero approved vaccines for humans. The one that reached market, LYMErix, was withdrawn in 2002, and we return to that story in a moment. There is one recommended prophylaxis protocol, a single 200 mg dose of doxycycline within 72 hours of a recognized tick bite, effective only when the person notices the tick in the first place. There is one class of acute-phase therapy: doxycycline, amoxicillin, ceftriaxone. These help most people with early Lyme. They fail 10 to 20 percent of the time in ways we will now examine in detail.

There is no approved therapy for Powassan. Supportive care only. When the virus crosses the blood-brain barrier, the family waits. There is no cure for alpha-gal syndrome, and patients are told to avoid mammalian meat and gelatin for life. There is no cure for post-treatment Lyme disease syndrome, and roughly one in five Lyme patients is told to live with fatigue, joint pain, and cognitive dysfunction indefinitely.

Every one of these gaps is the same gap. The medical model has attacked the pathogen. On Long Island, that model has been losing ground every year for a decade.

Why the Studies Failed. All of Them.

Before proposing a different approach we owe the reader a careful account of why the existing approaches have not worked. The failures are not accidents. They cluster into four categories and each one points at the same structural blind spot.

Failure One. The vaccine that worked and got pulled anyway.

LYMErix, licensed by SmithKline Beecham in December 1998, was approximately 78 percent effective against Lyme infection after three doses and 100 percent effective at preventing asymptomatic seroconversion. The FDA reviewed post-market surveillance and found insufficient evidence of a causal relationship between reported adverse events and the vaccine. The manufacturer withdrew it in February 2002, citing declining sales, class-action litigation, and public confusion about a discredited molecular-mimicry autoimmunity hypothesis, as documented in a Clinical Infectious Diseases retrospective. GlaxoSmithKline projected fewer than 10,000 doses in 2002. That was the end. As the same review concludes, future candidate Lyme vaccines are unlikely to be developed and used in the United States in the near future, leaving at-risk populations, including every family on Long Island, unprotected.

The lesson is not that vaccines cannot work against a tick-borne pathogen. LYMErix worked. The lesson is that a single-pathogen vaccine model, delivered by injection on a complicated three-dose schedule, cannot survive the commercial and political weather. And even if a new candidate reaches market, it would cover exactly one of the six pathogens now circulating on Long Island. Nobody is even attempting a vaccine for Powassan, babesiosis, anaplasmosis, Borrelia miyamotoi, or alpha-gal. The vaccine road is closed.

Failure Two. The antibiotic that leaves persisters behind.

Doxycycline is the workhorse. It clears the acute rash and most early symptoms in most patients. But the underlying biology of Borrelia burgdorferi defeats it in a specific and reproducible way. Peer-reviewed work published in Antimicrobial Agents and Chemotherapy demonstrated that Borrelia burgdorferi forms persister cells that survive concentrations of doxycycline, amoxicillin, and ceftriaxone that exceed what is clinically achievable in patients. These are not mutants. They are dormant phenotypic variants. Antibiotics need actively growing cells to work. Persisters go quiet, absorb the antibiotic pulse, and reactivate when the drug clears.

Additional work from Johns Hopkins showed that ceftriaxone pulse dosing fails to eradicate biofilm-like microcolony persisters, and that doxycycline is unsuitable for pulse dosing at all. Earlier work by Sapi and colleagues, reviewed in Frontiers in Cellular and Infection Microbiology, showed that doxycycline reduced spirochetal forms by 90 percent but doubled the number of round-body forms, and that the five most-used antibiotics as a group reduced biofilm-like colony formation by only 30 to 55 percent.

Translation for the Long Island family whose doctor said the antibiotics finished the job. In a meaningful fraction of patients the antibiotics did not finish the job. They knocked down the visible spirochetes and left a hidden reservoir the immune system now has to contain, forever.

Failure Three. The chronic phase nobody can treat.

The consequence of Failure Two is a syndrome the Infectious Diseases Society of America names post-treatment Lyme disease syndrome, or PTLDS. Approximately 10 to 20 percent of appropriately treated Lyme patients develop persistent fatigue, joint pain, and neurocognitive symptoms lasting six months or more, per the current PMC clinical review. A separate prospective cohort documented 27.2 percent prevalence of persistent symptoms at one year in physician-confirmed Lyme patients, roughly 4 to 6 points above matched reference cohorts. Independent work found 36 percent of treated patients reporting new-onset fatigue, 20 percent widespread pain, and 45 percent neurocognitive difficulty at six months, with 35 percent meeting the full IDSA case definition of PTLDS.

The proposed mechanisms behind PTLDS, as cataloged in the current mechanisms review, include tissue damage, chronic inflammation, immune dysregulation, autoimmunity, persistent infection, and coinfection with other tick-borne pathogens. Every one of those mechanisms depends on the same downstream biology. A cell whose antioxidant defense system has been broken cannot resolve inflammation, cannot repair oxidative damage, and cannot clear a persistent reservoir. We will now show that this is not speculation. It is the published biochemical signature of Borrelia infection.

Failure Four. Nobody targeted the antioxidant system.

Here is the finding that reframes the entire field. In a landmark PMC-published study of primary human monocytes exposed to Borrelia burgdorferi, pathway analysis identified glutathione metabolism as the pathway most significantly affected by the pathogen, with intracellular glutathione levels increasing on average tenfold, tenfold higher than LPS or Pam3Cys. The response was pathogen-specific. It was not seen with other stimuli. Even more revealing, gamma-glutamyl amino acids, direct products of glutathione metabolism, were altered in the serum of early Lyme patients and not in patients with other infections. The authors concluded that the glutathione pathway is essential for Borrelia-induced cytokine production and that glutathione metabolism and glutathionylation may be important factors in the pathogenesis of Lyme disease.

The single most affected biochemical pathway in Lyme disease is the same pathway every major virus attacks.

It is the same pathway hantavirus, SARS-CoV-2, influenza, HIV, hepatitis B and C, dengue, Ebola, and RSV attack, described in detail in the ReBaLU antiviral field guide. It is the pathway that governs whether a hijacked cell can clean up reactive oxygen species and whether a healthy cell can resist ferroptosis. It is the pathway the ReBaLU protocol was engineered to restore.

And it is not just Lyme. A 2022 systematic review in Frontiers in Cellular and Infection Microbiology surveyed the entire tick-borne disease landscape and concluded that inflammation and oxidative stress are key elements in the pathogenesis of tick-borne diseases, driving oxidative modifications of phospholipids and proteins and quantitative changes in reactive oxygen species and lipid mediators. Powassan, Anaplasma, Babesia, Borrelia miyamotoi, and Borrelia burgdorferi, on a mechanistic level, share the same downstream lesion. Redox collapse.

Nobody targeted it. Not the vaccine. Not the antibiotics. Not the acute-phase antivirals that do not exist. Every drug program aimed at the pathogen. The pathogen picked the same lock every time and the drug developers kept designing new keys for new doors.

What Every Long Island Tick-Borne Pathogen Actually Does Inside You

To make the point concrete, here is what each of the six pathogens now circulating in Suffolk County does to the antioxidant system it hijacks. The specifics differ. The pattern does not.

Borrelia burgdorferi (Lyme) corrupts glutathione metabolism as its dominant pathway effect, with tenfold shifts in intracellular glutathione that are specific to this pathogen and detectable in patient serum. Glutathionylation drives the cytokine response, then persister cells shelter inside biofilm-like microcolonies where the antioxidant collapse in surrounding tissue lets them survive antibiotic pressure.

Babesia microti (babesiosis) is a malaria-like protozoan that invades red blood cells. Hemolysis liberates free heme, a potent generator of reactive oxygen species. The GPX-4 and glutathione axis in erythrocytes and endothelium is overwhelmed, driving the anemia, kidney injury, and, in immunocompromised patients, mortality. Same redox lesion, different cell type.

Anaplasma phagocytophilum (anaplasmosis) actively subverts the NADPH oxidase system of the neutrophils it lives inside, preventing the host cell from producing the reactive oxygen species that would kill it while it replicates in the vacuole. The antioxidant machinery of that specific cell is turned against its host role. This is not conjecture. It is the well-documented mechanism of the disease.

Powassan virus is a flavivirus in the same family as tick-borne encephalitis, West Nile, and dengue. Every flavivirus studied to date suppresses Nrf2 in the neurons and endothelial cells it infects, generates a reactive oxygen species burden that damages the blood-brain barrier, and drives an inflammatory cascade the immune system cannot resolve because the host cells' antioxidant defense is offline. The 15 percent case fatality is a redox-driven encephalitis.

Borrelia miyamotoi (relapsing fever) runs cycles of high spirochetemia followed by immune clearance, then relapse. Each relapse cycle inflicts a fresh wave of oxidative damage on erythrocytes and endothelium. The pattern of relapse depends on host antioxidant capacity holding up between episodes. When it does not, patients progress.

Alpha-gal syndrome is the exception that proves the rule. It is not an infection. It is an IgE-mediated allergy to the galactose-alpha-1,3-galactose carbohydrate delivered by tick saliva. But the anaphylactic cascade it triggers is itself an oxidative-inflammatory storm dependent on mast cell degranulation and downstream lipid peroxidation, exactly the terrain a restored GPX-4 axis and adequate DHA membrane integrity are designed to blunt.

The ReBaLU Reframe

The ReBaLU protocol asks a question the tick-borne disease field has not asked. Instead of building a new drug or a new vaccine for each pathogen, what if we restore the host defense that all six pathogens have to break?

The mechanism, in plain language, is this. Every one of these pathogens survives inside your cells only as long as your antioxidant defense system, governed by the master regulator Nrf2 and executed by SOD2, GPX-1, GPX-4, and glutathione, stays broken. ReBaLU walks in behind the pathogen and re-locks the lock. It restores endogenous butyrate production inside your gut, mouth, and mucosal surfaces by feeding your own bacteria a precisely engineered prebiotic substrate of Tagatose, Fibersol-2, high-methoxy pectin, and microalgae oil. The butyrate is produced locally, slowly, at physiological levels, all day long, exactly as the body was designed to produce it. It selectively accumulates inside cells whose metabolism has been corrupted, and it turns the lights back on inside those cells specifically. The hijacked cells go through ferroptosis and apoptosis. The pathogen or its reservoir dies with them. The immune system sees the wreckage and finishes the job.

This is the point most researchers missed, and it is the reason the last fifteen years of butyrate studies looked discouraging. Every one of those studies used exogenous sodium butyrate, a chemist's salt, at supraphysiological doses of 2 to 5 millimolar. At those doses butyrate suppresses about 60 percent of interferon-stimulated genes and suppresses antiviral immunity. That is the trap. ReBaLU does the opposite. It produces butyrate endogenously, locally, at the concentrations your body is designed to handle, and at those concentrations butyrate restores Nrf2, restores GPX and SOD2 gene expression, and drives selective self-destruction only in the cells that have been hijacked. Different pathway. Different effect. Opposite outcome.

The full clinical framework, elaborated in the ReBaLU antiviral field guide, applies without modification to the Long Island tick problem. The pathogens are different. The lesion is the same. The protocol targets the lesion.

The Long Island Deployment Plan

Here is what a ReBaLU-based tick-borne disease strategy looks like operationally on Long Island. It is deployable this year. It does not require FDA approval because every ingredient is Generally Recognized As Safe. It does not require a doctor's prescription. It does not wait on a vaccine that will not come.

Phase 1. Test. Baseline the Long Island resident.

The SOD Sciences saliva panel is the entry point. It reads seven genetic markers that determine antioxidant factory settings: Nrf2 polymorphisms, SOD2 (Val16Ala), GPX-1 (Pro198Leu), GPX-4 status, APOE4 carrier status, TERT, and TKTL1. It also reads five dynamic biomarkers: total glutathione, DHA level, SOD2 activity, nitrate, and butyrate-producing capacity of the microbiome.

The single most consequential finding for the tick problem is APOE4 status. APOE4 carriers have approximately four times the viral mortality risk of non-carriers in published studies, and there is strong mechanistic reason to expect the same disadvantage against Powassan, severe babesiosis, and complicated Lyme. On Long Island, roughly 20 to 25 percent of the population carries at least one APOE4 allele. That is the high-risk cohort. They need to know before, not after.

Risk stratification returns Standard, Moderate, or High. High-risk residents get the full protocol plus the accelerant stack from day one, ahead of the May-through-October tick season.

Phase 2. Treat. Continuous seasonal preventive.

The core protocol runs during tick season for every Long Island resident who spends any time in the yard, on trails, or near deer habitat. That is essentially the entire county east of Route 110.

The sustained engine is the Essential Gummy. Two gummies, three times a day, delivering Tagatose, Fibersol-2, high-methoxy pectin, and microalgae oil to the colonic microbiome. It ramps to steady state in one to two weeks. The mouthwash runs morning and evening, swallowed, on the same substrate base. The oral microbiome starts producing local butyrate within hours and shapes immune signaling along the oral-respiratory axis. For Powassan, which is neuroinvasive but enters through a peripheral bite, the systemic antioxidant tone matters from the first hour of exposure. For women there is a daily vaginal wash, which supports Lactobacillus dominance and mucosal IgA at a documented immune site. It is relevant both to chronic tick-borne pathology and to the immune-modulatory role of the vaginal microbiome in systemic infection.

For High-risk residents and anyone with a recognized recent bite, the acute-exposure accelerant stack is added for the first two to three weeks. Sulforaphane 30 to 50 mg per day as the fastest direct Nrf2 activator through Keap1 modification. NAC 600 to 1200 mg per day as the direct glutathione precursor. Selenium 200 mcg per day as the GPX cofactor. Zinc 15 to 30 mg per day to sharpen natural killer cell cytotoxicity so that DAMP-flagged hijacked cells get cleared cleanly. For a suspected Powassan exposure, where the fifteen-minute transmission window means most residents will not know until symptoms appear, running the accelerant stack for the balance of tick season is a defensible risk-adjusted position for any APOE4 carrier.

Phase 3. Retest. Every quarter.

The biomarker panel repeats every three months. Is glutathione trending toward normal. Is DHA adequate. Is SOD2 activity restored. Is butyrate-producing capacity of the microbiome improving. If yes, continue. If no, escalate to the High-risk protocol and consult a physician. This is what turns a supplement stack into personalized antioxidant medicine.

Why This Solution Was Never Explored Before

Four reasons, each of them structural.

One. The commercial model rewards single-pathogen assets, not host-directed platforms. A Powassan-specific antiviral, a Babesia-specific antiparasitic, a next-generation Lyme vaccine. Each of these fits inside a fifteen-year, one-to-three-billion-dollar development program the pharma industry knows how to fund. A GRAS-based host-defense protocol that works on all six pathogens at once fits inside no such program. Nobody funded it because nobody could patent the underlying biology, only the specific formulations and delivery systems, which is what SOD Sciences has done.

Two. The published butyrate literature scared everyone off. The exogenous versus endogenous distinction is subtle and it was missed. Fifteen years of investigators reading the sodium butyrate suppresses antiviral immunity papers concluded that butyrate was a dead end for infectious disease. They were reading the papers correctly and drawing the wrong operational conclusion. ReBaLU is the first protocol built specifically around endogenous, physiological, local butyrate production.

Three. Tick-borne disease research is fragmented across pathogen silos. The Lyme researchers do not talk to the Powassan researchers who do not talk to the babesiosis researchers. The redox-imbalance finding in the Frontiers review is roughly four years old, and its integrative implication, that all tick-borne pathogens share a downstream lesion the host can be reinforced to survive, has not been translated into a clinical program by any group other than SOD Sciences.

Four. Nobody built the personalized testing infrastructure. The APOE4 mortality signal, the SOD2 and GPX polymorphism biology, the saliva biomarker panel that lets you calibrate an intervention to an individual host. This infrastructure did not exist. SOD Sciences built it. The panel exists now.

Put those four together and you have a platform that solves a problem the world was told to accept as unsolvable, and it exists because the ReBaLU thesis was assembled by people who did not accept the frame. The lock is the same lock. The pathogen is not the point. The host is the point.

What This Means for Long Island

Suffolk County has, roughly, 1.5 million residents. If 20 percent are APOE4 carriers, that is 300,000 High-risk residents who need to know their status and run the full protocol seasonally. If another 40 percent carry a single-axis antioxidant vulnerability, that is another 600,000 Moderate-risk residents on the core protocol. The remaining 600,000 run the Standard preventive package during tick season.

A single Powassan death prevented, a single case of PTLDS avoided, a single anaphylaxis event averted in an alpha-gal patient, each of these has a measurable clinical and economic value. Multiplied across a county whose tick disease burden is growing at compound double digits every year, the case for a deployable, GRAS, host-directed platform is not incremental. It is structural.

Every family on Long Island whose child came home from a summer at camp with an EM rash and a doxycycline prescription deserves to know that the antibiotic is one layer, that persister cells can survive it, that the antioxidant collapse it leaves behind is the substrate of chronic Lyme, and that a protocol designed specifically to restore that antioxidant system exists and is deployable now.

Every long COVID patient on Long Island who was told the fatigue was in their head, and every PTLDS patient who was told the same thing about their Lyme, is describing the same underlying lesion. Persistent reservoir cells depend on chronic Nrf2 suppression. Sustained pressure on those reservoir cells with endogenous butyrate, DHA, and the supporting Nrf2 activators is the only mechanistically grounded approach that addresses the root cause and not the symptoms.

The world does not have a Lyme vaccine coming. The world does not have a Powassan antiviral coming. The world does not have an alpha-gal cure coming. What the world has is a GRAS-ingredient protocol built on twenty years of oxidative-stress and microbiome biology, engineered around the one weakness every tick-borne pathogen shares.

Deployable through the gut, the mouth, and the mucosa. Tested against an individual host's genetic and biomarker profile. Refined quarterly. That is the unlock. That is what has never been explored before. And Long Island, the county with the highest tick-borne disease burden in the United States, is the place to prove it.

Sources

Frontiers in Cellular and Infection Microbiology (2022). Redox Imbalance and Its Metabolic Consequences in Tick-Borne Diseases. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2022.870398/full

PMC (2018). Role of glutathione metabolism in host defense against Borrelia burgdorferi infection. https://pmc.ncbi.nlm.nih.gov/articles/PMC5877983/

North Fork Sun. Tick season never ends: the East End's growing threat from Lyme, alpha-gal, and more. https://northforksun.com/tick-season-never-ends-the-east-ends-growing-threat-from-lyme-alpha-gal-and-more/

AABB (2026). CDC Reports Record Powassan Virus Activity as West Nile Cases Decline in 2024. https://www.aabb.org/news-resources/news/article/2026/08/05/cdc-reports-record-powassan-virus-activity-as-west-nile-cases-decline-in-2024

CDC. Powassan Virus Historic Data, 2004 to 2024. https://www.cdc.gov/powassan/data-maps/historic-data.html

Clinical Infectious Diseases. Vaccines against Lyme Disease: What Happened and What Lessons Can We Learn? https://academic.oup.com/cid/article/52/suppl_3/s253/444754

PMC. The Lyme vaccine: a cautionary tale. https://pmc.ncbi.nlm.nih.gov/articles/PMC2870557/

History of Vaccines. Lyme Disease. https://historyofvaccines.org/diseases/lyme-disease/

Antimicrobial Agents and Chemotherapy. Borrelia burgdorferi Forms Drug-Tolerant Persister Cells. https://journals.asm.org/doi/10.1128/aac.00864-15

Johns Hopkins. Ceftriaxone pulse dosing fails to eradicate biofilm-like microcolony B. burgdorferi persisters. https://pure.johnshopkins.edu/en/publications/ceftriaxone-pulse-dosing-fails-to-eradicate-biofilm-like-microcol

PMC. Quorum Sensing and Persister Cells in Borrelia. https://pmc.ncbi.nlm.nih.gov/articles/PMC3636972/

PMC. Lyme Disease and Post-treatment Lyme Disease Syndrome. https://pmc.ncbi.nlm.nih.gov/articles/PMC10483257/

PMC. Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome. https://pmc.ncbi.nlm.nih.gov/articles/PMC11332314/

PMC. Prevalence of persistent symptoms after treatment for Lyme borreliosis. https://pmc.ncbi.nlm.nih.gov/articles/PMC8454881/

PMC. Post-treatment Lyme disease syndrome symptomatology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3548099/

Tick-borne infections can be serious and can progress quickly. Anyone with a known tick bite, an expanding rash, fever, headache, joint swelling, or neurological symptoms should seek medical evaluation without delay. Nothing described here is a substitute for diagnosis and treatment by a physician, and nothing here is a reason to delay, decline, or discontinue antibiotic therapy.

This document presents a scientific hypothesis for discussion. It is not medical advice. The proposed intervention has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

SOD Sciences Inc. Science Brief, August 2026.